Additionally, exploratory subgroup analyses highlighted the value of using NGS to identify tumour mutational status and suggested that capivasertib predominantly benefited participants with PI3K/AKT/PTEN pathway-altered tumours. The gene discussed is PIK3CA; the disease is neoplasm.